Other Operating Income: 6.32----Total Income From Operations: 390.21: 410.55: 449.64: EXPENDITURE ...

Indoco Remedies' share price rose after the company received final USFDA approval for its ANDA to market Allopurinol tablets ...

Indoco Remedies board of directors has proposed a final dividend of ₹0.20 per equity share of face value of ₹2 each ...

Mumbai: Indoco Remedies Ltd. has announced the final approval of Allopurinol Tablets USP 200 mg through its Abbreviated New ...

Following the earnings announcement, shares of Indoco Remedies saw sharp fall. The stock fell over 12% from its day’s high of ...

Quarterly Net Loss at Rs. 26.24 crore in March 2025 down 169.86% from Rs. 37.56 crore in March 2024. EBITDA stands at Rs.

Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric ...

Indoco Remedies receives US FDA final approval to market allopurinol tablets USP 200 mg: Our Bureau, Mumbai Friday, May 23, 2025, 12:30 Hrs [IST] Indoco Remedies Ltd., a fully int ...

Our Bureau, New Delhi Friday, May 23, 2025, 10:30 Hrs [IST] Indoco Remedies has reported a net loss of Rs. 41.34 crore ...

Traders will monitor IndusInd Bank Ltd., InterGlobe Aviation Ltd., Oil and Natural Gas Corp., and Ircon International Ltd.

Indoco has gained permission from the Food and Drug Administration for lofexidine tablets 0.18 mg, which is a generic of USWM’s Lucemyra Tablets. Indoco has been granted a Competitive Generic ...

Get the annual and quarterly balance sheet of Indoco Remedies Limited (INDOCO.BO) including details of assets, liabilities and shareholders' equity.